Skip to content

The prevalence and risk factors of ischemic and bleeding events in patients with coronary artery disease treated with antiplatelet drugs

The prevalence and risk factors of ischemic and bleeding events in patients with coronary artery disease treated with antiplatelet drugs

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075026
Enrollment
Unknown
Registered
2023-08-23
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

group with high immature platelet fraction(IPF):None
group with low IPF:None

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 and 80 years old, men or women; 2.Patients with coronary artery disease diagnosed by coronary angiography with diameter stenosis = 50% in at least one coronary artery. 3.Undergoing antiplatelet therapy with aspirin, or P2Y12 receptor antagonist such as clopidogrel or ticagrelor, or dual-antiplatelet therapy: aspirin+ clopidogrel or ticagrelor;

Exclusion criteria

Exclusion criteria: 1.Intolerance or allergy to aspirin, clopidogrel or ticagrelor; 2.Long-term concomitant need for oral anticoagulants, glucocorticoids or non-steroidal anti-inflammatory drugs; 3. Severe hematological disorders,such as disorders in platelet production and functions, hemoglobin < 90g/L or coagulation disorders, etc.; 4.Active bleeding or severe bleeding event within 3 months (BARC=2); 5.Blood transfusion within 30 days; 6.Other severe diseases, such as severe liver insufficiency (Child Pugh B or C), chronic renal insufficiency requiring dialysis, serious infection or malignant neoplastic diseases, etc; 7.Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
the incidence of major adverse cardiovascular event (MACE);

Secondary

MeasureTime frame
the incidence of bleeding event (BARC=2);the all-cause mortality;

Countries

China

Contacts

Public ContactRuqiong Nie

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

nierq@mail.sysu.edu.cn+86 20 8133 3407

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026